Skip to main content
Top
Published in: Techniques in Coloproctology 9/2016

Open Access 01-09-2016 | Original Article

Pro-inflammatory cytokines in cryptoglandular anal fistulas

Authors: R. S. van Onkelen, M. P. Gosselink, M. van Meurs, M. J. Melief, W. R. Schouten, J. D. Laman

Published in: Techniques in Coloproctology | Issue 9/2016

Login to get access

Abstract

Background

Sphincter-preserving procedures for the treatment of transsphincteric fistulas fail in at least one out of every three patients. It has been suggested that failure is due to ongoing disease in the remaining fistula tract. Cytokines play an important role in inflammation. At present, biologicals targeting cytokines are available. Therefore, detection and identification of cytokines in anal fistulas might have implications for future treatment modalities. The objective of the present study was to assess local production of a selected panel of cytokines in anal fistulas, including pro-inflammatory interleukin (IL)-1β and tumor necrosis factor α (TNF-α).

Methods

Fistula tract tissue was obtained from 27 patients with a transsphincteric fistula of cryptoglandular origin who underwent flap repair, ligation of the intersphincteric fistula tract or a combination of both procedures. Patients with a rectovaginal fistula or a fistula due to Crohn’s disease were excluded. Frozen tissue samples were sectioned and stained using advanced immuno-enzyme staining methods for detection of selected cytokines, IL-1β, IL-8, IL-10, IL-12p40, IL-17A, IL-18, IL-36 and TNF-α. The presence and frequencies of cytokine-producing cells in samples were quantitated.

Results

The key finding was abundant expression of IL-1β in 93 % of the anal fistulas. Frequencies of IL-1β-producing cells were highest (>50 positive stained cells) in 7 % of the anal fistulas. Also, cytokines IL-8, IL-12p40 and TNF-α were present in respectively 70, 33 and 30 % of the anal fistulas.

Conclusions

IL-1β is expressed in the large majority of cryptoglandular anal fistulas, as well as several other pro-inflammatory cytokines.
Literature
1.
go back to reference Mitalas LE, Gosselink MP, Zimmerman DDE, Schouten WR (2007) Repeat transanal advancement flap repair: impact on the overall healing rate of high transsphincteric fistulas and on fecal continence. Dis Colon Rectum 50:1508–1511CrossRefPubMedPubMedCentral Mitalas LE, Gosselink MP, Zimmerman DDE, Schouten WR (2007) Repeat transanal advancement flap repair: impact on the overall healing rate of high transsphincteric fistulas and on fecal continence. Dis Colon Rectum 50:1508–1511CrossRefPubMedPubMedCentral
2.
go back to reference Mitalas LE, van Onkelen RS, Monkhorst K, Zimmerman DD, Gosselink MP, Schouten WR (2012) Identification of epithelialization in high transsphincteric fistulas. Tech Coloproctol 16:113–117CrossRefPubMedPubMedCentral Mitalas LE, van Onkelen RS, Monkhorst K, Zimmerman DD, Gosselink MP, Schouten WR (2012) Identification of epithelialization in high transsphincteric fistulas. Tech Coloproctol 16:113–117CrossRefPubMedPubMedCentral
3.
go back to reference van Onkelen RS, Mitalas LE, Gosselink MP, van Belkum A, Laman JD, Schouten WR (2013) Assessment of microbiota and peptidoglycan in perianal fistulas. Diagn Microbiol Infect Dis 75:50–54CrossRefPubMed van Onkelen RS, Mitalas LE, Gosselink MP, van Belkum A, Laman JD, Schouten WR (2013) Assessment of microbiota and peptidoglycan in perianal fistulas. Diagn Microbiol Infect Dis 75:50–54CrossRefPubMed
4.
go back to reference Tozer PJ, Rayment N, Hart AL et al (2015) What role do bacteria play in persisting fistula formation in idiopathic and Crohn’s anal fistula? Colorectal Dis 17:235–241CrossRefPubMed Tozer PJ, Rayment N, Hart AL et al (2015) What role do bacteria play in persisting fistula formation in idiopathic and Crohn’s anal fistula? Colorectal Dis 17:235–241CrossRefPubMed
5.
go back to reference Martinon F, Agostini L, Meylan E, Tschopp J (2004) Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14:1929–1934CrossRefPubMed Martinon F, Agostini L, Meylan E, Tschopp J (2004) Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14:1929–1934CrossRefPubMed
6.
go back to reference van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA (2011) Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol 32:110–116CrossRefPubMed van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA (2011) Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol 32:110–116CrossRefPubMed
7.
go back to reference Inohara N, Ogura Y, Fontalba A et al (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 278:5509–5512CrossRefPubMed Inohara N, Ogura Y, Fontalba A et al (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 278:5509–5512CrossRefPubMed
8.
go back to reference Laman JD, Schoneveld AH, Moll FL, van Meurs M, Pasterkamp G (2002) Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am J Cardiol 90:119–123CrossRefPubMed Laman JD, Schoneveld AH, Moll FL, van Meurs M, Pasterkamp G (2002) Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am J Cardiol 90:119–123CrossRefPubMed
9.
go back to reference Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364–371CrossRefPubMed Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364–371CrossRefPubMed
10.
go back to reference Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89–91CrossRefPubMed Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89–91CrossRefPubMed
11.
go back to reference Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705–1709CrossRefPubMedPubMedCentral Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705–1709CrossRefPubMedPubMedCentral
12.
go back to reference Dinarello CA, Simon A, van der Meer JWM (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652CrossRefPubMedPubMedCentral Dinarello CA, Simon A, van der Meer JWM (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652CrossRefPubMedPubMedCentral
14.
go back to reference Cruse JM, Lewis RE (2009) Illustrated dictionary of immunology, 3rd edn. CRC Press, LondonCrossRef Cruse JM, Lewis RE (2009) Illustrated dictionary of immunology, 3rd edn. CRC Press, LondonCrossRef
15.
16.
go back to reference Gresnigt MS, van de Veerdonk FL (2013) Biology of IL-36 cytokines and their role in disease. Semin Immunol 25:458–465CrossRefPubMed Gresnigt MS, van de Veerdonk FL (2013) Biology of IL-36 cytokines and their role in disease. Semin Immunol 25:458–465CrossRefPubMed
17.
go back to reference Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad AR (2015) Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74:27–34CrossRefPubMed Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad AR (2015) Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74:27–34CrossRefPubMed
18.
go back to reference van Onkelen RS, Gosselink MP, Schouten WR (2012) Is it possible to improve the outcome of transanal advancement flap repair for high transsphincteric fistulas by additional ligation of the intersphincteric fistula tract? Dis Colon Rectum 55:163–166CrossRefPubMed van Onkelen RS, Gosselink MP, Schouten WR (2012) Is it possible to improve the outcome of transanal advancement flap repair for high transsphincteric fistulas by additional ligation of the intersphincteric fistula tract? Dis Colon Rectum 55:163–166CrossRefPubMed
19.
go back to reference Ning Y, Manegold PC, Hong YK et al (2011) Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 128:2038–2049CrossRefPubMedPubMedCentral Ning Y, Manegold PC, Hong YK et al (2011) Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 128:2038–2049CrossRefPubMedPubMedCentral
20.
21.
go back to reference Dinarello CA, Ikejima T, Warner SJ et al (1987) Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 139:1902–1910PubMed Dinarello CA, Ikejima T, Warner SJ et al (1987) Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 139:1902–1910PubMed
22.
go back to reference Schouten WR, Zimmerman DDE, Briel JW (1999) Transanal advancement flap repair of transsphincteric fistulas. Dis Colon Rectum 42:1419–1422CrossRefPubMed Schouten WR, Zimmerman DDE, Briel JW (1999) Transanal advancement flap repair of transsphincteric fistulas. Dis Colon Rectum 42:1419–1422CrossRefPubMed
23.
go back to reference van Koperen PJ, Bemelman WA, Gerhards MF et al (2011) The anal fistula plug treatment compared with the mucosal advancement flap for cryptoglandular high transsphincteric perianal fistula: a double-blinded multicenter randomized trial. Dis Colon Rectum 54:387–393CrossRefPubMed van Koperen PJ, Bemelman WA, Gerhards MF et al (2011) The anal fistula plug treatment compared with the mucosal advancement flap for cryptoglandular high transsphincteric perianal fistula: a double-blinded multicenter randomized trial. Dis Colon Rectum 54:387–393CrossRefPubMed
24.
go back to reference van der Hagen SJ, Baeten CG, Soeters PB, van Gemert WG (2011) Autologous platelet-derived growth factors (platelet-rich plasma) as an adjunct to mucosal advancement flap in high cryptoglandular perianal fistulae: a pilot study. Colorectal Dis 13:215–218CrossRefPubMed van der Hagen SJ, Baeten CG, Soeters PB, van Gemert WG (2011) Autologous platelet-derived growth factors (platelet-rich plasma) as an adjunct to mucosal advancement flap in high cryptoglandular perianal fistulae: a pilot study. Colorectal Dis 13:215–218CrossRefPubMed
25.
go back to reference Göttgens KW, Vening W, van der Hagen SJ et al (2014) Long-term results of mucosal advancement flap combined with platelet-rich plasma for high cryptoglandular perianal fistulas. Dis Colon Rectum 57:223–227CrossRefPubMed Göttgens KW, Vening W, van der Hagen SJ et al (2014) Long-term results of mucosal advancement flap combined with platelet-rich plasma for high cryptoglandular perianal fistulas. Dis Colon Rectum 57:223–227CrossRefPubMed
26.
go back to reference Kim HJ, Yeom JS, Koh YG et al (2014) Anti-inflammatory effect of platelet-rich plasma on nucleus pulposus cells with response of TNF-α and IL-1. J Orthop Res 32:551–556CrossRefPubMed Kim HJ, Yeom JS, Koh YG et al (2014) Anti-inflammatory effect of platelet-rich plasma on nucleus pulposus cells with response of TNF-α and IL-1. J Orthop Res 32:551–556CrossRefPubMed
27.
go back to reference Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD (2014) An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 70:243–251CrossRefPubMed Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD (2014) An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 70:243–251CrossRefPubMed
Metadata
Title
Pro-inflammatory cytokines in cryptoglandular anal fistulas
Authors
R. S. van Onkelen
M. P. Gosselink
M. van Meurs
M. J. Melief
W. R. Schouten
J. D. Laman
Publication date
01-09-2016
Publisher
Springer International Publishing
Published in
Techniques in Coloproctology / Issue 9/2016
Print ISSN: 1123-6337
Electronic ISSN: 1128-045X
DOI
https://doi.org/10.1007/s10151-016-1494-7

Other articles of this Issue 9/2016

Techniques in Coloproctology 9/2016 Go to the issue